Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Biocytogen (百奥赛图) Pre-IPO: Prospectus and Valuation Updates

Biocytogen (百奥赛图) IPO: Short Term and Long Term Challenges

Biocytogen (百奥赛图) IPO Trading: Week Demand

Biocytogen (百奥赛图) Pre-IPO: From Animal CRO to Biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Biocytogen Pharmaceuticals (Beijing) / Equity Capital Markets

Biocytogen Pharmaceuticals (Beijing) (2315 HK)

<ul>
<li>Biocytogen, a China-based pre-clinical research and biopharmaceutical company, plans to raise up to USD 300m via a Hong Kong listing.</li>
<li>We compared the company's key metrics with its close peer in the animal CRO segment.</li>
<li>We provide a preliminary thought on the valuation for its animal CRO.</li>
</ul>


Biocytogen, a China-based pre-clinical research and biopharmaceutical company, plans to raise up to USD 300m via a Hong Kong listing.
We compared the company's key metrics with its close peer in the animal CRO segment.
We provide a preliminary thought on the valuation for its animal CRO.


Biocytogen (百奥赛图) Pre-IPO: Peer Comparison and Prelim Valuation for Animal CRO